Akinlolu O. Ojo

Akinlolu O. Ojo

Auto-generated profile, based on publicly available information

Akinlolu O. Ojo

Department of Internal Medicine

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2003 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AOAkinlolu O. Ojo
Akinlolu O. Ojo
PHPhilip J. Held
Philip J. Held
FPFriedrich K. Port
Friedrich K. Port
RWRobert A. Wolfe
Robert A. Wolfe
ALAlan B. Leichtman
Alan B. Leichtman
RMRobert M. Merion
Robert M. Merion
Transplantation of nonrenal organs is often complicated by chronic renal disease with multifactorial causes. We conducted a population-based cohort analysis to evaluate the incidence of chronic renal failure, risk factors for it, and the associated hazard of death in recipients of nonrenal transplants. Pretransplantation and post-transplantation clinical variables and data from a registry of patients with end-stage renal disease (ESRD) were linked in order to estimate the cumulative incidence of chronic renal failure (defined as a glomerular filtration rate of 29 ml per minute per 1.73 m2 of body-surface area or less or the development of ESRD) and the associated risk of death among 69,321 persons who received nonrenal transplants in the United States between 1990 and 2000. During a median follow-up of 36 months, chronic renal failure developed in 11,426 patients (16.5 percent). Of these patients, 3297 (28.9 percent) required maintenance dialysis or renal transplantation. The five-year risk of chronic renal failure varied according to the type of organ transplanted — from 6.9 percent among recipients of heart–lung transplants to 21.3 percent among recipients of intestine transplants. Multivariate analysis indicated that an increased risk of chronic renal failure was associated with increasing age (relative risk per 10-year increment, 1.36; P<0.001), female sex (relative risk among male patients as compared with female patients, 0.74; P<0.001), pretransplantation hepatitis C infection (relative risk, 1.15; P<0.001), hypertension (relative risk, 1.18; P<0.001), diabetes mellitus (relative risk, 1.42; P<0.001), and postoperative acute renal failure (relative risk, 2.13; P<0.001). The occurrence of chronic renal failure significantly increased the risk of death (relative risk, 4.55; P<0.001). Treatment of ESRD with kidney transplantation was associated with a five-year risk of death that was significantly lower than that associated with dialysis (relative risk, 0.56; P=0.02). The five-year risk of chronic renal failure after transplantation of a nonrenal organ ranges from 7 to 21 percent, depending on the type of organ transplanted. The occurrence of chronic renal failure among patients with a nonrenal transplant is associated with an increase by a factor of more than four in the risk of death.

1 January 2000 in Kidney International
Verified
Journal Article
Closed access
AOAkinlolu O. Ojo
Akinlolu O. Ojo
JHJulie A. Hanson
Julie A. Hanson
RWRobert A. Wolfe
Robert A. Wolfe
ALAlan B. Leichtman
Alan B. Leichtman
LALawrence Y. Agodoa
Lawrence Y. Agodoa
FPFriedrich K. Port
Friedrich K. Port

1 March 2001 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
AOAkinlolu O. Ojo
Akinlolu O. Ojo
JHJulie A. Hanson
Julie A. Hanson
HMHerwig-Ulf Meier-Kriesche
Herwig-Ulf Meier-Kriesche
COChike N. Okechukwu
Chike N. Okechukwu
RWRobert A. Wolfe
Robert A. Wolfe
FPFriedrich K. Port
Friedrich K. Port
: An increasing number of cadaveric kidney transplants are now performed with organs from donors who would have been deemed unsuitable in earlier times. Although good allograft outcomes have been obtained with these marginal donor transplants, it is unclear whether recipients of marginal kidney transplants achieve a reduction in long-term mortality as do recipients of “ideal” kidneys. Patients with end-stage renal disease registered on the cadaveric renal transplant waiting list between January 1, 1992, and June 30, 1997, were studied for mortality risks according to three outcomes: wait-listed on dialysis treatment with no transplant (WLD); transplantation with marginal donor kidney (MDK); and “ideal” or optimal donor kidney transplantation (IDK). Thirty-four percent of wait-list registrants had received a cadaveric kidney transplant by June 30, 1998. Of these, 18% received a marginal kidney that had one or more of the following pretransplant factors: donor age >55 yr, non-heartbeating donor, cold ischemia time >36 h, and donor hypertension or diabetes mellitus of > 10 yr duration. Five-year graft and patient survival was 53% and 74% for MDK recipients compared with 67% (P < 0.001) and 80% (P < 0.001) for IDK recipients. Adjusted annual death rate and estimated remaining life time was 6.3%, 4.7%, and 3.3% and 15.3 yr, 20.4 yr, and 28.7 yr for WLD, MDK, and IDK groups, respectively. The average increase in life expectancy for MDK recipients compared with the WLD cohort was 5 yr, although this benefit varied from 3 to 10 yr depending on the recipient's characteristics. It is concluded that transplantation of a marginal kidney is associated with a significant survival benefit when compared with maintenance dialysis.

27 December 1998 in Transplantation
Verified
Journal Article
Closed access
AOAkinlolu O. Ojo
Akinlolu O. Ojo
RWRobert A. Wolfe
Robert A. Wolfe
LALawrence Y. Agodoa
Lawrence Y. Agodoa
PHPhilip J. Held
Philip J. Held
FPFriedrich K. Port
Friedrich K. Port
ALAlan B. Leichtman
Alan B. Leichtman
Background. Survival of transplant recipients after primary renal allograft failure has not been well studied. Methods. A cohort of 19,208 renal transplant recipients with primary allograft failure between 1985 and 1995 were followed from the date of allograft loss until death, repeat transplantation, or December 31, 1996. The mortality, wait-listing, and repeat transplantation rates were assessed. The mortality risks associated with repeat transplantation were estimated with a time-dependent survival model. Results. In total, 34.5% (n=6,631) of patients died during follow-up. Of these deaths, 82.9% (n=5,498) occurred in patients not wait-listed for repeat transplantation, 11.9% (n=789) occurred in wait-listed patients, and 5.2% (n=344) occurred in second transplant recipients. Before repeat transplantation, the adjusted 5-year patient survival was 36%, 49%, and 65% for type I diabetes mellitus (DM), type II DM, and nondiabetic end-stage renal disease, respectively (P<0.001; DM vs. nondiabetics). The adjusted 5-year patient survival was lower in Caucasians (57%, P<0.001) compared with African-Americans (67%) and other races (64%). The 5-yr repeat transplantation rate was 29%, 15%, and 19%, whereas the median waiting time for a second transplant was 32, 90, and 81 months for Caucasians, African-Americans, and other races, respectively (P<0.0001 each). Repeat transplantation was associated with 45% and 23% reduction in 5-year mortality for type I DM and nondiabetic end-stage renal disease, respectively, when compared with their wait-listed dialysis counterparts with prior transplant failure. Conclusions. The loss of a primary renal allograft was associated with significant mortality, especially in recipients with type I DM. Repeat transplantation was associated with a substantial improvement in 5-year patient survival. Recipients with type I DM achieved the greatest proportional benefit from repeat transplantation.

1 November 2009 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
PRPanduranga S. Rao
Panduranga S. Rao
AOAkinlolu Ojo
Akinlolu Ojo
There is significant variability in the quality of deceased-donor kidneys that are used for transplantation. The quality of the donor kidney has a direct effect on important clinical outcomes such as acute rejection, delayed graft function, and patient and allograft survival. Expanded-criteria donors (ECDs) refer to older kidney donors (≥60 yr) or donors who are aged 50 to 59 yr and have two of the following three features: Hypertension, terminal serum creatinine >1.5 mg/dl, or death from cerebrovascular accident. By definition, ECD kidneys have a 70% greater likelihood of failure compared with one from a 35-yr-old male donor who died from a motor vehicle accident. Donation after cardiac death (DCD) is a small but rapidly growing fraction of donors. An ECD kidney transplant recipient has a projected average added-life-years of 5.1 yr compared with 10 yr for a kidney recipient from a standard-criteria donor. Kidney transplantation from DCD seems to have similar allograft and patient survival compared with kidney from donation after brain death; however DCD transplantation has a 42 to 51% risk for delayed graft function (need for at least one dialysis treatment during the first week after transplantation) compared with 24% in an standard-criteria donor kidney transplant. Familiarity with the comprehensive allocation rules governing different categories of deceased-donor kidneys by the nephrologists and dialysis team providers is essential to maximizing patient autonomy and to improve the outcomes of kidney transplantation.

1 April 2003 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
HNHoward M. Nathan
Howard M. Nathan
SCSuzanne L. Conrad
Suzanne L. Conrad
PHPhilip J. Held
Philip J. Held
KMKeith P. McCullough
Keith P. McCullough
RPRichard E. Pietroski
Richard E. Pietroski
AOAkinlolu O. Ojo
Akinlolu O. Ojo
Click on the article title to read more.